AYTU BIOPHARMA, INC (AYTU)
2025-03-31 | 2024-09-30 | |||
|---|---|---|---|---|
| Net revenue | 18,452 | 16,574 | ||
| Cost of sales | 5,646 | 4,589 | ||
| Gross profit | 12,806 | 11,985 | ||
| Restructuring costs | - | 784 | ||
| Selling and marketing | 5,194 | 5,659 | ||
| Research and development | 162 | 426 | ||
| General and administrative | 4,109 | 5,125 | ||
| Amortization of intangible assets | 920 | 921 | ||
| Total operating expenses | 10,385 | 12,915 | ||
| Income (loss) from operations | 2,421 | -930 | ||
| Interest expense | 900 | 994 | ||
| Derivative, gain (loss) on derivative, net | 2,261 | 2,880 | ||
| Other income, net | 36 | 542 | ||
| Income (loss) from continuing operations before income tax expense | 3,818 | 1,498 | ||
| Income tax benefit (expense) | -122 | 405 | ||
| Net income (loss) from continuing operations | 3,940 | 1,093 | ||
| Net income (loss) from discontinued operations, net of tax | 54 | - | ||
| Net income (loss) from discontinued operations, net of tax | - | 381 | ||
| Net income (loss) | 3,994 | 1,474 | ||
| Basic eps | 0.65 | 0.24 | ||
| Diluted eps | 0.21 | -0.15 | ||
| Basic average shares | 6,134,634 | 6,068,019 | ||
| Diluted average shares | 8,204,453 | 9,099,601 | ||